NYR.ASX: First Cohort Dosed in Nyradas Phase I Clinical Trial

First Cohort Dosed in Nyradas Phase I Clinical Trial

Stock	Nyrada Inc (NYR.ASX)
Release Time	31 Mar 2025, 9:52 a.m.
Price Sensitive	Yes

This feature provides summaries of price-sensitive announcements for companies followed by users on InvestorPA. The summaries are generated by large language models so please interpret with care.

First Cohort Dosed in Nyrada's Phase I Clinical Trial

Key Points

First cohort of participants dosed in Nyrada's Phase I first-in-human clinical trial
Six participants received NYR-BI03 while two participants received placebo
Phase I trial designed to assess safety, tolerability and pharmacokinetics of NYR-BI03

Full Summary

Nyrada Inc. (ASX:NYR), a drug discovery and development company focused on innovative Transient Receptor Potential Canonical (TRPC) ion channel blockers, has announced the completion of dosing in the first cohort of its Phase I clinical trial for lead drug candidate NYR-BI03. The trial is designed to assess the safety, tolerability, and pharmacokinetics of NYR-BI03. Two sentinel participants were dosed initially, one receiving NYR-BI03 and the other receiving a placebo. The remainder of participants in the cohort were then dosed, with a total of six participants receiving NYR-BI03 and an additional two receiving a placebo in this double-blind, randomised, placebo-controlled, dose-escalation study. The dose of either NYR-BI03 or placebo was administered by infusion over three hours. After each completed cohort, the Safety Review Committee (SRC) will review accumulated safety and pharmacokinetic data, and subsequent dose cohorts may only proceed after favourable review and approval by the SRC. Final Phase I trial readouts are expected in the third quarter of 2025, and regular updates will be provided throughout the trial.